The 3E-Program

The 3E-Study

From June 30, 2008, to March 30, 2009, 73 end-stage cancer patients participated in a five-week 3E-program. The goal was to teach these end-stage patients about the accounts of similarly-diagnosed cases and how the latter succeeded in returning to their normal lives despite the inexplicably terminal prognosis.

Of the 73 patients, six have undergone operations, were tumor-free, and have decided against obtaining further conventional therapies.  The remaining 67 patients, however, all had conventionally-diagnosed tumors at the time of admission.

From the 67 cases, 19 had inoperable tumors while 16 had R0-resections with subsequent recurrences. Meanwhile, the remaining 32 patients had undergone surgery as well as chemotherapy and/or radiation but experienced recurrences as well.

At the end of the study, on March 30, 2010, the patients returned for their report. Thirty-six (53%) of the 67 terminal patients were still alive – about triple their supposed life expectancy of 6 months. Eight of these patients were tumor-free, despite 7 of whom initially had partial multiple metastases and one case with inoperable glioblastoma.

Another 15 patients had a stable disease which means tumor growth has stopped. Also, the PET scans of two patients with pancreatic carcinoma revealed normal Standardized Uptake Values (SUVs). Although the SUVs indicated no tumor-mass reduction, the data showed a significant decrease in tumor activity.

Just three out of the surviving 36 cases reported feeling worse off by the end of the study than at their discharge. Meanwhile, the six tumor-free patients continued to be well with no reported relapses.

Naturally, we’re incredibly proud that more than half of our 3E-Program participants were still alive and well after two years, particularly the fact that several of them were completely tumor-free. Save for three; all the brave cancer survivors had no further tumor growth. We are unaware of a study with more positive results anywhere else in the world!

Admittedly, we are aware that this data does not come from a randomized, double-blind study of an institution or university, nor is our Program – including all our therapies, research, and knowledge – recognized in the world of conventional medicine. However, we have no desire to get into the sad details as to why proven and successful cancer therapies do not receive the recognition they deserve. We are cognizant of the fact that treatments like these are not just snubbed in Germany but many other countries as well.

Nonetheless, for patients, all verifiable, made survivors by these treatments the current political state of affairs does not matter.  The patients survived by 100%, not 36% nor 67%, but 100%. Naturally, we are infinitely grateful for this knowledge and all the therapies that, according to convention, are supposedly pointless for cancer patients. We know that pharmaceutical companies, and often physicians as well, love statistics. Ultimately, though, for cancer, it’s either 100% or zero.

All our 67 participants were diagnosed with metastatic cancer which, according to conventional medicine, means their chances of long-term survival was 0%. Prognosis notwithstanding, 36 of these patients continued living two years after and many are still alive today. The appalling flaw here is this: when doctors say they can no longer help, most patients hear “no man can help you. It’s futile.” In contrast, if only patients understood that they can help themselves and that there is more to the fight against cancer than chemo and radiation, then other measures and new paths can be taken especially when everyone says it’s hopeless.